IONS IONIS PHARMACEUTICALS INC Insider Trading

EVP C Frank Bennett sold 20,536 shares at blended $84.95 on 2026-07-07 under 10b5-1 plan; stock now $64.27, down 25.9% from high.

C Frank Bennett, EVP and Chief Scientific Officer, executed 2 separate sales totaling 20,536 shares for $1,744,623.34 on 2026-07-07 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-31. The shares sold at a blended average price of $84.95; the stock currently trades at $64.27, representing a decline of 25.9% from the 52-week high of $86.74. Bennett retains 12,109 restricted stock units post-transaction. His prior trades at IONS (5 distinct sales between February and March 2026) experienced negative returns within 30 and 90 days, with 90-day outcomes ranging from -4.7% to -9.3%, suggesting his selling has historically preceded further downward price movement at this ticker. The company reported a net loss of $92,528,000.00 in the latest quarter and remains unprofitable on a full-year basis, though revenue grew 33.8% year-over-year. The scheduled nature of the transaction via 10b5-1 plan removes discretionary timing as an interpretive lens.

EVP Eugene Schneider sold 26,000 IONS shares at $81.05 under 10b5-1 plan; retains 77,114 shares plus 26,000 options.

Eugene Schneider, EVP and Chief Clinical Development Officer, sold 26,000 shares (26.0K shares) of IONIS PHARMACEUTICALS INC (IONS) at $81.05 on 2026-06-26 for $2,107,196.00 ($2.1M) under a pre-arranged 10b5-1 trading plan adopted on 2025-11-19, reducing his non-derivative holdings from 103,114 to 77,114 shares (-25.2% vs pre-transaction holdings). The sale was scheduled, not discretionary. His same-ticker prior sales in September 2025 posted strong subsequent returns: 30d +14.4%/+12.6%, 90d +34.5%/+32.4%, though the December 2023 sale showed minimal 30d return (+0.2%) and negative 90d return (-14.7%), indicating inconsistent near-term directional outcomes. IONS remains unprofitable (net income $-92,528,000.00 over the latest full fiscal year) despite strong revenue growth of +33.8% annually and an improving stock trajectory (+3.6% over 30 days, +5.5% over 90 days). Derivative holdings of 26,000 non-qualified stock options remain post-transaction, so his overall exposure is not fully reduced.

Ionis CEO Brett P Monia sells 85,637 shares for $6.8M under pre-arranged 10b5-1 plan (2026-06-24 to 2026-06-26)

Brett P Monia executed 3 separate sales totaling 85,637 shares for $6,825,523.71 on 2026-06-24 through 2026-06-26, reducing non-derivative holdings from 331,208 to 245,571 shares (-25.9% of pre-transaction holdings). The sales were conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-12-08, meaning this is a scheduled, non-discretionary transaction sequence rather than a discretionary market decision. At the time of sale, the stock traded in the range of $78.41–$80.59 (blended average $79.70); the current price is $81.18, reflecting minimal divergence from the execution prices. While the CEO retains 245,571 non-derivative shares post-transaction, significant derivative holdings totaling 120,944 shares in non-qualified stock options remain outstanding, preserving material ongoing equity exposure. The company is unprofitable (net income of -$92,528,000.00 over the most recent full fiscal year) but has grown revenue at +33.8% annually.

EVP Holly Kordasiewicz sells 60,846 shares for $4,466,427.82 under 10b5-1 plan; retains 22,458 shares plus 21,000 stock options

Holly B. Kordasiewicz, EVP and Chief Development Officer, executed 2 separate sales totaling 60,846 shares for $4,466,427.82 on 2026-06-12 under a pre-arranged 10b5-1 trading plan adopted 2026-03-13. Her non-derivative holdings decreased from 83,304 shares to 22,458 shares (a 73.0% reduction), though she retains 21,000 shares in the form of non-qualified stock options. The company is currently unprofitable (net income of $-92,528,000 for the latest full fiscal year) despite strong revenue growth of 33.8% year-over-year and recent quarterly revenue of $246,091,000. The stock trades at $73.09, down 15.7% from its 52-week high of $86.74, placing this sale as a scheduled execution within a predetermined plan rather than a discretionary market-timing decision.

Director Joseph Loscalzo exercised options and sold all acquired shares on same day; proceeds exceed $5.8M despite unprofitable fundamentals.

Director Joseph Loscalzo executed a mechanical exercise-and-sell sequence on a single day: acquiring 77,289 shares across six option exercises at prices ranging from $38 to $64, then immediately selling all 77,289 shares at prices near $75, netting approximately $2M in proceeds. This is classic tax-efficient equity compensation vesting, not a bet on the company's direction. Loscalzo's sole prior Form 4 activity was a sale in October 2025, whose outcome is not yet measurable, so no timing pattern can be established from his previous trades at this stock. Ionis itself remains unprofitable on an annual basis despite strong revenue growth, and the stock is trading noticeably below its 52-week high—context that makes the exercise-and-sell pattern routine compensation management rather than a statement about conviction in the business. The net zero share change confirms no cumulative accumulation or reduction in his exposure occurred.

Director Klein sold 22,321 shares for $1.7M under pre-arranged 10b5-1 plan (adopted Nov 2025)

Director Joseph Klein III sold 22,321 shares across 2 separate transactions on April 1, 2026, reducing his holdings from 33,335 shares to 11,014 shares (a -67.0% reduction). The sales were executed under a 10b5-1 trading plan adopted on 2025-11-26, meaning this was a scheduled, non-discretionary transaction rather than a discretionary market decision. At a blended average price of $75.55 per share, the total proceeds were $1,686,301.88. Since the trade is plan-governed and not discretionary, the price level and timing do not signal the insider's real-time conviction or market view—they reflect mechanistic execution of a predetermined schedule. The substantial reduction in holdings warrants investor monitoring to understand whether this reflects a previously scheduled liquidity event or a change in Klein's broader position management.

IONS CFO Elizabeth Hougen sold 225,220 shares for $16.3M under pre-arranged 10b5-1 plan

Elizabeth Hougen, EVP Finance & CFO at Ionis Pharmaceuticals, executed 3 separate sales totaling 225,220 shares for $16,313,675.85 across March 16-17, 2026, at blended average price of $72.43. Her post-transaction holdings of 82,660 shares represent a -73.2% reduction versus pre-transaction holdings of 307,880 shares. This transaction is governed by a pre-arranged 10b5-1 trading plan adopted on 2025-12-09, meaning the sales were scheduled rather than discretionary. The substantial reduction in her share position reflects the mechanical operation of the plan established months prior to execution.

EVP Jenne Kyle sells 37,277 shares for $2,827,324.68 via pre-arranged 10b5-1 plan, reducing holdings by 69.5%.

Jenne Kyle, EVP and Chief Global Product Strategy Officer, executed 2 separate sales totaling 37,277 shares for $2,827,324.68 on 2026-03-10 at an average price of $75.85 per share. This sale reduced her post-transaction holdings to 16,389 shares from a pre-transaction position of 53,666 shares, representing a 69.5% reduction in her shareholding. The transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-12-08, making this a scheduled, non-discretionary sale rather than a discretionary trading decision. The substantial reduction in her direct ownership stake merits tracking in the context of her strategic role at the company.

IONS EVP/CLO O'Neil sells 10,148 shares at $75.25; stock down 11.8% in 30d; unprofitable company.

O'NEIL PATRICK R., EVP CLO & General Counsel, sold 10,148 shares of IONIS PHARMACEUTICALS INC at $75.25 on 2026-03-09, reducing his holdings by 14.0% to 62,211 shares. The stock has declined 11.8% over the 30 days following the transaction and is currently at $74.79, down 13.5% from its 52-week high of $86.50. At IONIS specifically, his prior 3 measurable sales all generated positive 90-day returns (+15.0%, +14.0%, +16.9%), meaning the stock rose after each of those sales—none were well-timed as sell decisions. IONIS remains unprofitable with net income of $-128,606,000.00 in its most recent fiscal year, despite strong quarterly revenue of $156,719,000.00 and annual revenue growth of +33.8%, creating a tension between growth momentum and profitability that warrants investor attention.

CEO Monia Brett sells 160,773 shares (39.9% of holdings) for $12.1M across 5 transactions on 2026-03-09/10 under 10b5-1 plan adopted 2025-12-08

CEO Monia Brett executed 5 separate sales totaling 160,773 shares for $12,114,155.19 at a blended average price of $75.35, reducing her holdings from 403,435 shares to 242,662 shares. The transactions span two days (2026-03-09 and 2026-03-10) across a narrow price range ($74.11 to $76.34), and are conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-12-08, making them scheduled rather than discretionary in nature. The 39.9% reduction in CEO equity stake represents a material disposition, though the scheduled framework removes any inference about market timing or conviction signals. Investors should note the substantial divestiture magnitude and monitor whether similar scheduled sales continue under the existing plan.